Heidi Hamm

From left, Sheila Collins, PhD, Ryan Ceddia, PhD, and Heidi Hamm, PhD, and their colleagues have identified a potential new approach to reducing the global impact of obesity and diabetes. (photo by Erin O. Smith)

Releasing a brake that drives obesity and diabetes

Vanderbilt researchers have uncovered a potential new way to help curb the rapidly rising worldwide prevalence of metabolic disorders, including obesity and diabetes.

Vanderbilt scientists report new modeling of brain signaling

The release of neurotransmitters and hormones in the body is tightly controlled by complex protein machinery embedded in cell membranes.

Reducing antidepressants’ side effects

Vanderbilt investigators have discovered how antidepressant medicines that block serotonin uptake can increase bleeding risk.

VUMC investigators honored by ASPET

Vanderbilt’s Heidi Hamm, Ph.D., and L. Jackson Roberts II, M.D., have been lauded by the American Society for Pharmacology and Experimental Therapeutics (ASPET).

Hamm’s lasting impact commended at Flexner Discovery Lecture

Pharmacology reached new heights on Hamm’s watch

During her 13-year tenure as chair of Vanderbilt University’s Department of Pharmacology, Heidi Hamm, Ph.D., bolstered its international reputation, attracted 18 new faculty members and helped take it in new directions, such as drug discovery.